Searching the Genome for Determinants of Response to HIV
David Goldstein
Duke Univ, Durham, NC, US

Genotyping Technologies: Small- and Large-scale Studies
Kevin Shianna
Inst for Genome Sci and Policy, Duke Univ, Durham, NC, US

Practical Applications in HIV Disease
Amalio Telenti
Univ of Lausanne, Switzerland

Intrinsic Immunity against Retroviruses in Primate Genomes: Evolutionary Retrospectives and Prospectives
Harmit Malik
Fred Hutchinson Cancer Res Ctr, Seattle, WA, US

Genetic Cohorts and Applications in Pharmacogenetics
David Haas
Vanderbilt Univ Sch of Med, Nashville, TN, US

12th Annual Bernard Fields Memorial Lecture: Greetings from the Program Committee
Mario Stevenson
Univ of Massachusetts Med Sch, Worcester, US

12th Annual Bernard Fields Memorial Lecture: HIV Co-receptors: From Postulates and Proofs to Perspectives and Promises
Edward Berger
NIAID, NIH, Bethesda, MD, US

Inaugural N'Galy-Mann Lecture: Intersection of Research and Clinical Care: The Cornell-GHESKIO Experience in Haiti
Jean Pape
Weill Med Coll of Cornell Univ, New York, NY, US

This Is Your Brain Off Drugs: Neurocognitive Function before and after ART Discontinuation in Patients with High CD4 Nadir (ACTG A5170)
Kevin Robertson
Univ of North Carolina at Chapel Hill, US

HIV-1-associated Dementia Associated with HIV DNA within Monocytes in Subjects Treated or Not Treated with ARV Medications
Bruce Shiramizu
Univ of Hawaii John A Burns Sch of Med, Honolulu, US

Predictors of Cerebrospinal Fluid Viral Burden during Primary HIV-1 Infection
Serena Spudich
Univ of California, San Francisco, US

MRS Can Detect HIV-induced Inflammation and Oxidative Stress in the Lenticular Nuclei
Beau Ances
Univ of California, San Diego, US

Longitudinal Stability of Psychomotor Speed and Cognitive Flexibility in Long-term Asymptomatic HIV-infected Individuals
Michael Cole
Univ of California, Los Angeles Med Ctr, US

Altered Diffusion Scalar Metrics in the Midsagittal Corpus Callosum Are Associated with Cognition among HIV Patients
David Tate
Ctr for AIDS Res, The Miriam Hosp, Providence, RI, US

Progressive Multifocal Leukoencephalopathy in the Era of HAART
David Clifford
Washington Univ, St Louis, MO, US

Virus Evolution Reveals LEDGF/p75 Is the Sole Mediator of Chromosomal Tethering
Zeger Debyser
Katholieke Univ, Leuven, Belgium

Mechanism of TRIM5a Restriction
Thomas Hope
Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US

Whole Genome Analysis Identifies a Susceptibility Locus to HIV-1
Corinne Loeuillet
Univ Hosp, Univ of Lausanne, Switzerland

Identification and Characterization of Viral MicroRNA Encoded by 2 AIDS-related Opportunistic Herpesviruses
Xuezhong Cai
Duke Univ, Durham, NC, US

HIV-1 Infection Unleashes Retrotransposition of Endogenous Elements
Brad Jones
Univ of Toronto, Canada

7SL RNA Is a Co-factor of the Antiviral Cytidine Deaminase APOBEC3G
Tao Wang
Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US

Phenotyping for Drug Interactions: Cocktails Anyone?
Angela Kashuba
Univ of North Carolina at Chapel Hill, US

Concentrations of Lopinavir and Ritonavir in Hair Are Strongly Correlated with Virologic Success
Monica Gandhi
Univ of California, San Francisco, US

Bioequivalence of Pilot Tablet Formulations of Ritonavir to the Marketed Soft Gel Capsule at a Dose of 100 mg
George Hanna
Abbott Labs, Abbott Park, IL, US

Cell-dependent Compartmentalization of Zidovudine- and Lamivudine-triphosphate Concentrations in HIV-seronegative Adults
Peter L. Anderson
Univ of Colorado Hlth Sci Ctr, Denver, US

Central Role of Escape Mutation in HIV Pathogenesis
Otto Yang
Univ of California, Los Angeles

Microbial Translocation Is a Cause of Systemic Immune Activation in Chronic HIV Infection
Jason Brenchley
Vaccine Res Ctr, NIAID, NIH Bethesda, MD, US

PD-1^hi SIV-specific CD8⁺ T Cells Express Multiple Effector Function and Have Low Proliferative Capacity and High Sensitivity to Activation-induced Cell Death
Consatntinos Petrovas
Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US

CD4 Reconstitution of Lymphoid Tissues Is Dependent on Earlier Initiation of HAART
Jacob Estes
Univ of Minnesota, Minneapolis, US

HIV-1 Subtype D Infection Is Associated with Faster Disease Progression than Subtype A, in Spite of Similar HIV-1 Plasma Viral Loads
Jared Baeten
Univ of Washington, Seattle, US

Mucosal CD4⁺ T Cell Depletion and Transient Immune Activation during the Early Phase of Non-pathogenic SIV Infection of Sooty Mangabeys
Shari Gordon
Emory Vaccine Ctr and Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US

PD-1 Expression on HIV-specific CD4⁺ T Cells Is Driven by HIV Replication and Is Associated with T-cell Dysfunction
Brent Palmer
Univ of Colorado Hlth Sci Ctr, Denver, US

Co-receptor Switch in a Macaque Infected with CCR5 (R5)-tropic Simian-Human Immunodeficiency Virus
Siu-Hong Ho
Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US

HVTN Experience with NIAID's Vaccine Research Center's Multiclade, Multigene Preventive HIV Vaccine Approach
Michael Keefer
Univ of Rochester, NY, US

EV02, a Phase I Trial to Assess the Safety and Immunogenicity of DNA-C followed by NYVAC-C in an Open, Randomized Comparison to NYVAC-C Alone in Healthy Volunteers at Low Risk of HIV Infection
Pierre-Alexandre Bart
Ctr Hosp Univ Vaudois Lausanne, Switzerland

Safety and Immunogenicity of the VRC Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine Alone or in Combination with the VRC Multiclade HIV-1 DNA Plasmid Vaccine in Healthy African Adults
Kayitesi Kayitenkore
Rwanda Zambia HIV Res Group, Kigali and Lusaka

Scientific Overview: Status of HIV Vaccine Efficacy Trials
Merlin Robb
US Military HIV Res Prgm, Rockville, MD

Initial Viral Decay to Assess the Relative Antiretroviral Potency of PI-, NNRTI-, and NRTI-Sparing Regimens for First Line Therapy of HIV-1 Infection: ACTG 5160s
Richard H. Haubrich
Univ of California, San Diego, US

Randomized Comparison in Treatment-naïve Patients of Once-daily vs Twice-daily Lopinavir/ritonavir-based ART and Comparison of Once-daily Self-administered vs Directly Observed Therapy
Robert Gross
Univ of Pennsylvania Sch of Med, Philadephia, US

Comparison of Plasma HIV-1 RNA, CD4 Cell Count, and CD38 Expression on CD8 T Cells as Predictors of Progression to AIDS and CD4 Cell Decline among Untreated Participants in the Multicenter AIDS Cohort Study
John Mellors
Univ of Pittsburgh, PA, US

Predictive Value of Plasma HIV RNA Levels for Rate of CD4 Decline and Clinical Disease Progression
Bryan Lau
Johns Hopkins Univ, Baltimore, MD, US

Carriage of HLA-Bw4 Is associated with lower CD4 Cell Counts after Starting HAART: Consistent Findings in the Western Australian HIV Cohort Study and the Swiss HIV Cohort Study
Andri Rauch
Univ Hosp, Berne, Switzerland

Disparities in Survival Attributable to Suboptimal HIV Care in the US: Influence of Gender and Race/Ethnicity
Elena Losina
Massachusetts Gen Hosp, Boston, US and Boston Univ Sch of Publ Hlth, MA, US

The HIV Integrase Inhibitor GS-9137 Demonstrates Potent ARV Activity in Treatment-experienced Patients
Andrew Zolopa
Stanford Univ, CA, US

48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients
Anton Pozniak
Chelsea and Westminster Hosp, London, UK

Exodus and Genesis: The Emergence of HIV-1 Group M Subtype B
Michael Worobey
Univ of Arizona, Tucson, US

HIV-1 Transmission Dynamics in an Urban North American Setting
Bluma Brenner
McGill AIDS Ctr, Jewish Gen Hosp, Montreal, Canada

Despite HAART, HIV-1 Is Once again Spreading Epidemically among Men Having Sex with Men in the Netherlands
Daniela Bezemer
HIV Monitoring Fndn, Amsterdam, The Netherlands

Correlates of Incident HIV Diagnosis, Knowledge of Chemoprophylaxis, and Burden of Acute and Recent Infection among Patrons of New York City Bathhouses: A Pilot Study
Demetre Daskalakis
New York Univ Sch of Med, NY, US

Population-based Prevalence Estimates of Diagnosed and Undiagnosed HIV and Associated Risk Behaviors among New York City Adults, 2004
Trang Quyen Nguyen
New York City Dept of Hlth and Mental Hygiene, New York, NY, US and CDC, Atlanta, GA, US

Impact of HSV-2 Suppressive Therapy on Genital and Plasma HIV-1 RNA in HIV-1 and HSV-2-seropositive Women Not Taking ART: A Randomized, Placebocontrolled Trial in Johannesburg, South Africa
Sinead Delany
Reproductive Hlth and HIV Res Unit, Johannesburg, South Africa and London Sch of Hygiene and Tropical Med, UK;

Randomized Trial of Male Circumcision for HIV Prevention in Rakai, Uganda
Ronald Gray
Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US

The Effects of Male Circumcision on Genital Ulcer Disease and Urethral Symptoms, and on HIV Acquisition: An RCT in Rakai, Uganda
Maria Wawer presented by Ronald Gray
Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US

Acute Hepatitis C in Men Who Have Sex With Men Is Not Confined to Those Infected with HIV, and Their Number Continues to Increase
Daniel Richardson
Royal Sussex County Hosp, Brighton, UK

The Dynamics of HCV Transmission among Injection Drug Users in St. Petersburg, Russia: Sexual Transmission and Acquisition of HIV Cooperative Agreement Program
Elijah Paintsil
Yale Univ, New Haven, CT, US

HCV-specific CD8⁺ T Cells Produce TGF-β that Suppresses HCV-specific T-cell responses of HCV-mono-infected and HIV-co-infected Subjects
Nadia Alatrakchi
Beth Israel Deaconess Med Ctr, Harvard Med Sch, Boston, MA, US

HIV-specific T Cells Accumulate in the Liver in HCV/HIV Co-infection
Mario Ostrowski
Univ of Toronto, Canada

CpG Adjuvant + HBV Vaccination in HIV Infection Achieves Long-term Seroprotection for as Long as 5 Years
Curtis Cooper
Ottawa Hosp, Univ of Ottawa, Canada

Selection of HBV-resistant Mutants in HIV/HBV-co-infected Patients Failing ART with Anti-HBV Activity: Implications for Diagnostic and Vaccine Escape
Julie Sheldon
Hosp Carlos III, Madrid, Spain

The Anti-Hepatitis B Drug Entecavir Inhibits HIV-1 Replication and Selects HIV-1 Variants Resistant to ARV Drugs
Chloe Thio
Johns Hopkins Univ, Baltimore, MD, US

Pre-exposure Prophylaxis in Macaques against Rectal SIV Challenge by Mucosally Applied PMPA: Potential for Complementation of Microbicide and Vaccination Strategies
Martin Cranage
St George's, Univ of London, UK

The Effect of Suppressive Acyclovir Therapy on HIV Cervicovaginal Shedding in HIV- and HSV-2-infected Women, Chiang Rai, Thailand
Eileen Dunne
CDC, Atlanta, GA, US

Chlamydial and Gonococcal Infection among Gay and Bisexual Men at the Time of HIV⁺ Test Result: Implications for Co-treatment, San Francisco, 2004-2006
Katherine Scott
San Francisco Dept of Publ Hlth, CA, US

Potential Effect of ARV Chemoprophylaxis on HIV-1 Transmission in Resource-limited Settings
Ume Abbas
Univ of Pittsburgh, PA, US

Efavirenz vs Nevirapine-based ART Regimens: Adherence and Virologic Outcomes
Jean Nachega
Johns Hopkins Univ, Baltimore, MD, US

Determinants of Mortality among HIV-infected Individuals Receiving Home-based ART in Rural Uganda
David Moore
Global AIDS Prgm, CDC Uganda, Entebbe

Outcomes of Adults Receiving Second-line ART in Médecins Sans Frontières-supported Projects in Resources-limited Countries
Alexandra Calmy
St Vincent's Hosp, Sydney, Australia

Efficacy of Kaletra-based Second-line ART in Cambodia
Laurent Ferradini
Médecins Sans Frontières, Phnom Penh, Cambodia

Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic, ART-experienced Patients Infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-Week Results
Elna van der Ryst
Pfizer Global R&D, Sandwich, UK

Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic ART-experienced Patients Infected with CCR5-tropic HIV-1: 24-Week Results of a Phase 2b/3 Study in the US and Canada
Howard Mayer
Pfizer Global R&D, New London, CT, US;

Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus
David Cooper
Univ of New South Wales, Sydney, Australia

Results of BENCHMRK-2, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus
R Steigbigel
State Univ of New York at Stony Brook, US

Update on Current Microbicide Trials: Update on the CONRAD Cellulose Sulfate Trial, Preclinical Evaluation of Cellulose Sulfate
Gustavo Doncel
Eastern Virginia Med Sch, Norfolk, VA

Update on Current Microbicide Trials: CONRAD's Cellulose Sulfate HIV Prevention Trial
Lut Van Damme
CONRAD, Arlington, VA

HIV-related Immune Suppression after ART Predicts Risk of Non-opportunistic Diseases: Results from the FIRST Study
Jason Baker
Univ of Minnesota, Minneapolis, US and Hennepin County Med Ctr, Minneapolis, MN, US

Metabolic Outcomes of ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial Treatment of HIV-1 Infection
Richard H. Haubrich
Univ of California, San Diego, US

Ezetimibe's Effects on the LDL Cholesterol Levels of HIV-infected Patients Receiving HAART
David Wohl
Univ of North Carolina at Chapel Hill, US

Poly-L-lactic Acid Injections for Facial Lipoatrophy: A Randomized, Multicenter Trial
Dianne Carey
Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South Wales, Australia

Interruption of ART and Risk of Cardiovascular Disease: Findings from SMART
Andrew Phillips
Royal Free and Univ Coll London Med Sch, UK

Alendronate with Calcium and Vitamin D Supplementation Is Superior to Calcium and Vitamin D Alone in the Management of Decreased Bone Mineral Density in HIV-infected patients: Results of ACTG 5163
Grace McComsey
Case Western Reserve Univ, Cleveland, OH, US

Effects of a Nucleoside Reverse Transcriptase Inhibitor, Stavudine, on Insulin Sensitivity and Mitochondrial Function in Muscle of Healthy Adults
Steven Grinspoon
Massachusetts Gen Hosp, Harvard Med Sch, Boston, US

Significant Sparing of Peripheral Lipoatrophy by HIV Treatment with LPV/r + ZDV/3TC Induction followed by LPV/r Monotherapy Compared with EFV + ZDV/3TC
DW Cameron
Univ of Ottawa at The Ottawa Hosp, Canada

Effects of TH9507, a Growth Hormone Releasing Factor Analog, on HIV-associated Abdominal Fat Accumulation: A Multicenter, Double-blind Placebocontrolled Trial with 412 Randomized Patients
Steven Grinspoon
Massachusetts Gen Hosp, Harvard Med Sch, Boston, US

Next Generation of Inhibitors of HIV-1 Integrase Strand Transfer Inhibitor: Structural Diversity and Resistance Profiles
John Wai
Merck Res Labs, West Point, PA, US

Structures of HIV-1 Reverse Transcriptase Complexed with NNRTI TMC278: Conformational and Positional Adaptability Overcomes Resistance Mutations
Joe D. Bauman
Ctr for Advanced Biotech and Med, Rutgers Univ, Piscataway, NJ, US

Ternary Complex Formation Compromises the Inhibitory Effects of the RT-associated RNase H Inhibitor Β-thujaplicinol
Greg Beilhartz
McGill Univ, Montreal, Canada

3'-Azido-3'-Dideoxythimidine Selects Mutations in the Connection (A371V) and RNase H (Q509L) Domains of Reverse Transcriptase that Increase AZT Resistance in Combination with Thymidine Analog Mutations without Affecting the Rate of AZT Excision on a DNA/D
Jessica Brehm
Univ of Pittsburgh, PA, US

Suppression of Dual-tropic HIV-1 Variants by the CXCR4 Inhibitor AMD3100 Is Associated with Efficiency of CXCR4 Use and Clonal Composition of the Baseline Virus Population
Signe Fransen
Monogram Biosci, South San Francisco, CA, US

Nevirapine-resistant HIV-1 among Mozambican Infants Infected in Utero vs Intra-partum or Early Postpartum
Lisa Frenkel
Univ of Washington, Seattle, US

Short-course Zidovudine and Lamivudine or Singledose Nevirapine-containing PMTCT Compromises 12-Month Response to HAART in African Women, Abidjan, Côte d'Ivoire (2003-2006)
François Dabis
INSERM 593, Univ Victor Segalen, Bordeaux, France

Prevalence of HIV-1 Drug Resistance after Virologic Failure of First HAART Regimen in South Africa: Initial Results of the South Africa Resistance Cohort Study
Vincent Marconi
Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, US

Clinical Endpoints for Randomized Clinical Trials: All AIDS-defining Conditions Are Not Created Equal
Mike Saag
Royal Free and Univ Coll London Med Sch, UK

Early Mortality among Patients with HIV-associated TB in Africa: Implications for the Time to Initiate ART
Stephen Lawn
Desmond Tutu HIV Ctr, Faculty of Hlth Sci, Univ of Cape Town, South Africa and London Sch of Hygiene and Tropical Med, UK

Causes of Death in HIV-infected Adults with TB Admitted to 2 Hospitals in Soweto, South Africa
Neil Martinson
Johns Hopkins Univ Ctr for TB Res, Baltimore, MD, US and Univ of the Witwatersrand, Johannesburg, South Africa

Cotrimoxazole Prophylaxis Reduced the Early Mortality of HIV-infected Patients on ART in Malawi
David Lowrance
Global AIDS Prgm, CDC, Atlanta, GA, US

HIV-induced Immunodeficiency and Risk of Fatal AIDS-defining and Non-AIDS-defining Malignancies: Results from the D:A:D Study
Antonella D'Arminio Monforte
ICONA, Hosp San Paolo, Univ of Milan, Italy

The Estimated Burden of HIV Disease in Uganda, 2005-2010
Wolfgang Hladik
CDC Uganda, Entebbe

HIV Testing for Family Members of Hospitalized Patients in Uganda
Happy Walusaga
Mulago-Mbarara Teaching Hosp Joint AIDS Pgm, Uganda

Superinfection Susceptibility and Low Neutralizing Serum Responses in Treated Persons with Suppressed Plasma Viral RNA Levels
Robert Grant
Gladstone Inst of Virology and Immunology, Univ of California, San Francisco, US

Specific Amino Acids in the N-terminus of the gp41 Ectodomain Contribute to the Stabilization of a Soluble, Cleaved gp140 Envelope Glycoprotein from HIV-1
Antu Dey
Weill Med Coll, Cornell Univ, New York, NY, US

Presence of HLA Class I-associated Cytotoxic T Lymphocyte Escape Mutations in Chronic Untreated HIV Infection Is Significantly Correlated with Clinical Markers of More Severe Disease Progression
Zabrina Brumme
Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, US and BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada

Relationship between HLA Genotype and the Functional Profile of Antigen-specific CD8 T Cells
Alexandre Harari
Ctr Hosp Univ Vaudois Lausanne, Switzerland

A Polymorphism in the FγRIIIa Gene Is Associated with HIV Infection Risk
Donald Forthal
Univ of California, Irvine Sch of Med, US

Protective HLA Class I Alleles Select HIV-1 Mutants and Slow Disease Progression
John Frater
The James Martin 21st Century Sch, Oxford Univ, UK

Evidence of a Protective Role for Cytokine/Chemokine Production in HIV Infection
Joseph Casazza
Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US

Substantial CD4⁺ T-cell Recovery and Reconstitution of Tissue Architecture in Gut-associated Lymphoid Tissue in Advanced HIV-1 Infection following Initiation of HAART
Derek Shenefelt
Univ of Colorado Hlth Sci Ctr, Denver, US and Weber State Univ, Ogden, UT, US

Plasma ARV Concentrations in Breastfeeding Infants Whose Mothers Are Receiving HAART
Mark Mirochnick
Boston Univ, MA, US

Postnatal Transmission of HIV and Breast Milk Viral Load and Sodium Level during the First 4 Months of Breastfeeding
Katherine Semrau
Boston Univ, MA, US

No Benefit of Early Cessation of Breastfeeding at 4 Months on HIV-free Survival of Infants Born to HIVinfected Mothers in Zambia: The Zambia Exclusive Breastfeeding Study
Moses Sinkala
Lusaka District Hlth Management Team, Zambia

Maternal HSV-2 Cervicovaginal Shedding Increases the Risk of Intra-partum HIV-1 Transmission
Sara Whitehead
Thailand Ministry of Publ Hlth-CDC Collaboration, Nonthaburi

Alteration of Circulating Osteoimmune Factors May Be Responsible for Bone Metabolism Derangement in HIV-infected Children and Adolescents
Alessandra Viganò
L Sacco Hosp, Univ of Milan, Italy

Plasma Concentrations of Efavirenz and Lopinavir in Children with and without Rifampicin-based Antit-TB Treatment
Yuan Ren
Univ of Cape Town, South Africa

The Effect of Cotrimoxazole Prophylaxis and Insecticide-treated Bednets on the Risk of Malaria among HIV-infected Ugandan Children
Anne Gasasira
Makerere Univ Med Sch, Kampala, Uganda

Catalyzing the Care and Treatment of HIV-infected Children in Sub-Saharan Africa: Early Outcomes from 5 Baylor College of Medicine Centers
Mark Kline
Baylor Coll of Med Intl Pediatric AIDS Initiative, Houston, TX, US; Gaborone, Botswana; Kampala, Uganda; Maseru, Lesotho; Mbabane, Swaziland; Lilongwe, Malawi

HIV in Genital Fluids during Heterosexual Transmission
Debrah Boeras
Emory Univ, Atlanta, GA, US

Complex HIV-1 Populations Prior to Seroconversion in Men Who Have Sex with Men: Analysis of HIV-1 Plasma RNA Positive-Seronegative Subjects from the MACS
Geoffrey Gottlieb
Univ of Washington, Seattle, US

HIV-1 Envelopes from Acute and Chronic Infection Differ in Their Levels of Fusogenicity and Sensitivity to Inhibition with sCD4
Terri Wrin
Monogram Biosci, South San Francisco, CA, US

Immunodomination by HLA-B27- and HLA-B57-restricted HIV-1-specific T-cell Responses Results in Abrogation of other HLA-restricted Responses in Primary HIV-1 Infection
Hendrik Streeck
Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Med Sch, Boston, US

Early Treatment of Primary HIV-1 Infection Lowers the Viral Set Point
Radjin Steingrover
Academic Med Ctr, Univ of Amsterdam, The Netherlands

No Benefit from Early Treatment in Primary HIV-infection?
Christine Koegl
IMUC Res, Munich, Germany

Time to ART Resumption following Treatment Interruption Is Shorter for Individuals Immunized with HIV-Recombinant Canarypox Vaccine (Vcp1452) Compared to Placebo: The Manon-02 Trial
Brigitte Autran
Hosp Pitie-Salpetriere, Paris, France; Univ Pierre et Marie Curie, Paris, France; INSERM U543, Paris, France;

Repeated r-hIL-7 Doses Improve T-cell Recovery in HIV-1-infected Patients Enrolled in a Phase I/II Multicentric Study
Y. Levy
INSERM, Creteil, France and Henri Mondor Hosp, Creteil, France

rhIL7 in HIV-1-infected Subjects with CD4 T-cell Count >100cells/µL and Viral Load <50,000 copies/mL: Results from a Randomized, Placebo-controlled, Double-blinded Study (ACTG5214)
Irini Sereti
NIAID, NIH, Bethesda, MD, US

In Chronic HIV-1 infection, Cyclosporine A Provides No Sustained Immunologic Benefit to Persons Starting ART
Michael Lederman
Case Western Reserve Univ, Cleveland, OH, US

Prevention of HIV Transmission from Breastfeeding
Hoosen Coovadia
Doris Duke Med Res Inst, Univ of KwaZulu Natal, South Africa

Opening Comments
John Mellors
Univ of Pittsburgh, PA, US

Origins of HIV-1 and Viral Diversity
Beatrice Hahn
Univ of Alabama at Birmingham, US

Host Restriction Factors
Michael Malim
King's Coll London Sch of Med, UK

New Insights into HIV Pathogenesis
Ronald Swanstrom
Univ of North Carolina at Chapel Hill, US

Host Immunity and Prospects for an HIV Vaccine
Richard Koup
Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US

Changing Patterns of US and Global Epidemiology
Kevin De Cock
WHO, Geneva, Switzerland

Optimizing Maternal and Pediatric Care
Elaine Abrams
Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US

Current and Future ART
Robert Schooley
Univ of California, San Diego, US

Management of Chronic Viral Hepatitis in HIV-Infected Persons
David Thomas
Johns Hopkins Univ, Sch of Med, Baltimore, MD, US

Closing Comments
Scott Hammer
Columbia Univ Coll of Physicians and Surgeons, New York, NY, US

What's Driving the European HIV Epidemic?
Anne Johnson
Univ Coll London, UK

What's Driving the Global MSM Epidemic?
Frits Van Griensven
CDC Thailand

The STD - HIV Connection from Research to Action: Are We Lost in Translation?
Judith Wasserheit
Univ of Washington, Seattle, US

New HIV Prevention Technologies: What if They Work?
Ward Cates Jr
Family Hlth Intl, Research Triangle Park, NC, US

The Potential for Exploiting Host Restriction Factors for Therapy
Reuben Harris
Univ of Minnesota, Minneapolis, US

New Agents and New Paradigms: the Complexity of CCR5 Inhibition
Daniel Kuritzkes
Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, US

Important Issues in the Treatment of HIV-infected Women: Optimizing ART throughout Life
Shahin Lockman
Brigham and Women's Hosp, Boston, MA, US

Do Novel ART Strategies Have a Role in the Longterm Therapy of HIV Infection?
David Cooper
Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South Wales, Australia

Immunopathogenesis of Acute and Chronic Viral Hepatitis C
Barbara Rehermann
Natl Inst of Diabetes & Digestive & Kidney Diseases, NIH, Bethesda, MD, US

Staging Liver Disease in HIV/HCV-co-infected Persons: Is Liver Biopsy the Right Test?
David Thomas
Johns Hopkins Univ Sch of Med, Baltimore, MD, US

Treating Hepatitis C in HIV-infected Patients: Is Now the Right Time?
Raymund Chung
Massachusetts Gen Hosp, Boston, US

Managing HBV Infection in 2007
Chloe Thio
Johns Hopkins Univ, Baltimore, MD, US

The Role of Nef in Primate Lentiviral Pathogenesis
Frank Kirchhoff
Univ of Ulm, Germany

Immunoregulation in HIV Infection
Bruce Walker
Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, US

Understanding the Benign Nature of SIV Infection in Natural Hosts: Implications for AIDS Pathogenesis
Guido Silvestri
Univ of Pennsylvania Sch of Med, Philadephia, US

Interactions between Regulatory T Cells and HIV: a Complex Balancing Act
Claire Chougnet
Cincinnati Children's Hosp Res Fndn, OH, US

HIV among Adolescents and Young Adults in the US and Implications for Biomedical Prevention Trials
Jonathan Ellen
Johns Hopkins Univ Sch of Med, Baltimore, MD, US

The Prime of Our Lives: Immunological Fitness and Reconstitution in Adolescence and Early Adulthood
Paul Krogstad
David Geffen Sch of Med, Univ of California, Los Angeles AIDS Inst, US

Targeting Adolescents for HIV Vaccine Trails in South Africa
Glenda Gray
Univ of the Witwatersrand, Chris Hani Baragwanath Hosp, Soweto, South Africa

HPV-associated Cancers and HIV: Will HPV Vaccines Make a Difference?
Anna-Barbara Moscicki
Univ of California, San Francisco, US

Structual Basis for Membrane Targeting by the HIV-1 Gag Protein
Michael Summers
Howard Hughes Med Inst, Univ of Maryland, Baltimore, US

TIP47, a Cellular Cofactor Involved in HIV-1 Envelope Incorporation into Virions
Clarisse Berlioz-Torrent
Inst Cochin, Paris, France

Regulation of HIV-1 Nuclear Entry
Vineet KewalRamani
HIV Drug Resistance Prgm, NCI-Frederick, MD, US

Functions of Apobec3 Complexes and P Bodies
Tariq Rana
Univ of Massachusetts Med Sch, Worcester, US

SIV Infection in Wild Gorillas
Fran Van Heuverswyn
Inst for Res and Devt, Univ of Montpelier, France

Simian Foamy Virus Infection of Humans
Antoine Gessain
Pasteur Inst, Paris, France

Emergence of Novel Human T-lymphotropic Viruses
William Switzer
CDC, Atlanta, GA, US

Long-term Non-progression with HIV Infection: Lessons from HIV-2
Sarah Rowland-Jones
Med Res Council Labs, Oxford, UK

Introduction
David Ho
Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US

How Can T-cell-based Vaccines Protect against SIV and HIV?
Mario Roederer
Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US

Global Epidemiology of HIV: Risk Factors, Social Networks, and Inter-Subtype Recombinant Strains in Vaccine Trial Sites
Francine McCutchan
US Military HIV Res Prgm, Rockville, MD, US

How Can the Immunogenicity of pDNA Vaccines be Improved?
Michael Egan
Wyeth Res, Pearl River, NY, US

Strategies to Overcome Pre-existing Vector-specific Immunity
Dan Barouch
Beth Israel Deaconess Med Ctr, Boston, MA, US

RTI Mechanisms of Resistance and Interactions that Impact Response
Nicolas Sluis-Cremer
Univ of Pittsburgh Sch of Med, PA, US

Impact of Subtype on HIV Drug Resistance
Jonathan Schapiro
Natl Hemophilia Ctr, Sheba Med Ctr, Tel Hashomer, Israel

Transmission of HIV Drug Resistance and Treatment Response
Susan Little
Univ of California, San Diego, US

Clinical Implications of Low-frequency HIV-1 Variants
Jeffrey Johnson
CDC, Atlanta, GA, US

Transmission of Extreme Drug Resistant TB in South Africa and Implications for Infection Control in Health Care Settings
Karin Weyer
South African Med Res Council, Pretoria

Discussant
Paul Nunn
Stop TB Dept, World Hlth Org, Geneva, Switzerland

A Large Outbreak of Diarrheal Disease with High Mortality among Non-breastfed Children in Botswana, 2006: Implications for HIV Prevention Strategies and Child Health
Tracy Creek
CDC, Atlanta, GA, US

Discussant
Peggy Henderson
Department of Child and Adolescent Health and Development, WHO

Evolution of Counseling and Testing Policy and Practice in Sub-Saheran Africa: Implications for Improving Access to HIV Prevention and Care
Nafuna Wamai
Global AIDS Prgm, CDC Uganda, Entebbe

PMTCT of HIV in Resource-poor Settings - Why Are We Doing So Badly?
Marc Bulterys
CDC, Lusaka, Zambia